This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Halvorson, K. G. Articles by Mantyh, P. W. Search for Related Content PubMed PubMed Citation Articles by Halvorson, K. G. Articles by Mantyh, P. W.

A Blocking Antibody to Nerve Growth Factor Attenuates Skeletal Pain Induced by Prostate Tumor Cells Growing in Bone

¹ Neurosystems Center and Departments of Diagnostic and Biological Sciences, Psychiatry, Neuroscience, and Cancer Center, University of Minnesota; ² Research Service, Veteran's Affairs Medical Center, Minneapolis, Minnesota; ³ College of Veterinary Medicine and Office of Research, The Ohio State University, Columbus, Ohio; and ⁴ Rinat Neuroscience, Corp., Palo Alto, California

Requests for reprints: Patrick W. Mantyh, Department of Diagnostic and Biological Sciences, 18-208 Moos Tower, University of Minnesota, 515 Delaware Street Southeast, Minneapolis, MN 55455. Phone: 612-626-0180; Fax: 612-626-2565; E-mail: manty001{at}umn.edu.

Prostate cancer is unique in that bone is often the only clinically detectable site of metastasis. Prostate tumors that have metastasized to bone frequently induce bone pain which can be difficult to fully control as it seems to be driven simultaneously by inflammatory, neuropathic, and tumorigenic mechanisms. As nerve growth factor (NGF) has been shown to modulate inflammatory and some neuropathic pain states in animal models, an NGF-sequestering antibody was administered in a prostate model of bone cancer where significant bone formation and bone destruction occur simultaneously in the mouse femur. Administration of a blocking antibody to NGF produced a significant reduction in both early and late stage bone cancer pain–related behaviors that was greater than or equivalent to that achieved with acute administration of 10 or 30 mg/kg of morphine sulfate. In contrast, this therapy did not influence tumor-induced bone remodeling, osteoblast proliferation, osteoclastogenesis, tumor growth, or markers of sensory or sympathetic innervation in the skin or bone. One rather unique aspect of the sensory innervation of bone, that may partially explain the analgesic efficacy of anti-NGF therapy in relieving prostate cancer–induced bone pain, is that nearly all nerve fibers that innervate the bone express trkA and p75, and these are the receptors through which NGF sensitizes and/or activates nociceptors. The present results suggest that anti-NGF therapy may be effective in reducing pain and enhancing the quality of life in patients with prostate tumor–induced bone cancer pain.

This article has been cited by other articles:

				A. Delaney, S. M. Fleetwood-Walker, L. A. Colvin, and M. Fallon Translational medicine: cancer pain mechanisms and management Br. J. Anaesth., July 1, 2008; 101(1): 87 - 94. [Abstract] [Full Text] [PDF]

				H. Hondermarck Nerve Growth Factor: The Dark Side of the Icon Am. J. Pathol., April 1, 2008; 172(4): 865 - 867. [Abstract] [Full Text] [PDF]

				K. D. Wild, D. Bian, D. Zhu, J. Davis, A. W. Bannon, T. J. Zhang, and J.-C. Louis Antibodies to Nerve Growth Factor Reverse Established Tactile Allodynia in Rodent Models of Neuropathic Pain without Tolerance J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 282 - 287. [Abstract] [Full Text] [PDF]